Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement, FDA Fires 30 GLP-1 Compounding Warning Letters + Sotyktu PsA PDUFA Friday

Moderna agrees to pay up to $2.25 billion to settle the lipid nanoparticle patent dispute with GenevantSciences and Arbutus Biopharma — $950M upfront in July 2026, with $1.3B contingent on a government contractor immunity appeal under Section 1498. The settlement grants Moderna a global non-exclusive LNP license for infectious disease applications. FDA issues 30 warning letters to telehealth companies overcompounded GLP-1 marketing, its most aggressive enforcement action yet as the shortage-era legal basis for compounding erodes. GenoGenix manufacturingconcerns linked to three ER visits. BMS Sotyktu (deucravacitinib) PsA PDUFA Friday March 6 — Spherix survey shows 1 in 3 rheumatologists view it as substantial advance. GSK linerixibat PDUFA March 24 for PBC cholestatic pruritus. BridgeBio presents additional FORTIFY Phase 3 BBP-418 muscular dystrophy data at MDA conference.